Some South Africans can now purchase GLP-1 weight-loss drugs using “pay later” arrangements, according to reporting from Moneyweb and The Citizen. The coverage links the availability of these payment options to high costs that many patients face when trying to access the medicines.
Both outlets say the price pressure is pushing some people toward cheaper alternatives, including illicit or unregistered products. The reports frame the “pay later” model as a way to reduce upfront payment barriers, while also highlighting concerns that consumers may instead turn to options outside regulated supply channels if they cannot afford treatment.
While both sources discuss the same overall development—payment flexibility for GLP-1 drugs and the risk of unregulated alternatives—details such as the specific providers involved, eligibility criteria, and the exact terms of the deferred-payment schemes are not included in the provided excerpts. The emphasis across outlets remains on affordability, access, and the potential safety implications of diverting to unregistered medicines.
